Current status of 4-aminoquinoline resistance markers 18 years after cessation of chloroquine use for the treatment of uncomplicated falciparum malaria in the littoral coastline region of Cameroon

References

• World Health Organisation. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO
   Google Scholar
• Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg. 2001;64(1–2):85–96.
   PubMed Web of Science ®Google Scholar
• Bi Y, Tong S. Poverty and malaria in the Yunnan province, China. Infect Dis Poverty. 2014;3(1). 10.1186/2049-9957-3-32
   PubMedGoogle Scholar
• Ranson H, N’Guessan R, Lines J, et al. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitology. 2011;27:91–98.
   Google Scholar
• Comité Nationale de Lutte Contre le Paludisme. Cameroon National Malaria Control Programme (2006). Annual report [http://www.minsante.gov.cmassessedonthe8thofMar2021at2021Mar8th].
   Google Scholar
• Ringwald P, Keundjian A, Ekobo A, et al. Chimio resistance de P. falciparum en milieu urbain a Yaounde, Cameroun. Part 2: evaluation del’efficacite de l’amodiaquine et de l’association sulfadoxine-pyrimethamine pour le traitement de l’accès palustre simple a Plasmodium falciparum à Yaoundé, Cameroun. Trop Med Int Health. 2000;5(9):620–627.
   PubMedGoogle Scholar
• Deshpande S, Kuppast B. 4-aminoquinolines: an overview of antimalarial chemotherapy. Med Chem. 2016;6:1.
   Google Scholar
• Mbacham W, Evehe M, Mbulli A, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine (fansider) and mutation rates to anti-folate genes in different regions of Cameroon. Acta Trop. 2005;95S:337.
   Google Scholar
• Nji M, Ali IM, Moyeh MN, et al.Randomized non- inferiority and safety trial of dihydroartemisin-piperaquine and artesunate amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children Malar J 141 article no. 27, 2015
   PubMedGoogle Scholar
• WHO. Strategy for malaria elimination in the greater Mekong sub region (2015–2030). Geneva Switzerland: World Health Organization (WHO; 2015.
   Google Scholar
• Kyaw MP, Nyunt MH, Chit K, et al. reduced susceptibility of plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE. 2013;8(3):e57689.
   PubMed Web of Science ®Google Scholar
• Uwimana A, Legrand E, Stokes BH, et al. Emergence and clonal expansion of in vitro artemisinin-resistant plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602–1608.
   PubMed Web of Science ®Google Scholar
• Balikagala B, Fukuda N, Ikeda M, et al. Evidence of artemisinin-resistant Malaria in Africa. N Engl J Med. 2021;385(13):1163–1171.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Gil JP, Ferreira PM, et al. Björkman A: amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76 T and pfmdr1 86Y. Infect Genet Evol. 2006;6:309–314.
   PubMed Web of Science ®Google Scholar
• Djimde AA, Ogobara PD, Doumbo K, et al. molecular marker for chloroquine-resistant falciparum Malaria. N Engl J Med. 2001;344:257–263.
   PubMed Web of Science ®Google Scholar
• Das S, Mahapatra SK, Tripathy S, et al. Double mutation in the pfmdr1 gene is associated with emergence of chloroquine-resistant plasmodium falciparum Malaria in Eastern India. Antimicrob Agents Chemother. 2014;58(10):5909–5915.
   PubMed Web of Science ®Google Scholar
• Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–1966.
   PubMed Web of Science ®Google Scholar
• Omar SA, Makokha FW, Abdo F, et al. Prevalence of Plasmodium falciparum chloroquine resistant gene markers, Pfcrt-76 and Pfmdr1-86, eight years after cessation of chloroquine use in Mwea, Kenya. J Infect Developing Countries. 2007;1(2):195–201.
   Google Scholar
• Moyeh MN, Njimoh LN, Evehe MS, et al. Effects of drug policy changes on evolution of molecular markers of plasmodium falciparum resistance to chloroquine, amodiaquine, and sulphadoxine-pyrimethamine in the South West Region of Cameroon. Malar Res Treat. 2018: Article ID 7071383, https://doi.org/10.1155/2018/7071383
   Google Scholar
• World Health Organization. division of control of tropical diseases. assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Switzerland; 1996. Geneva.
   Google Scholar
• Duraisingh MT, Curtis J, Warhurst D. Plasmodium falciparum: detection of polymorphism in the dihydrofalate reductase and dihydropteroate synthase genes by PCR and restriction digestion. Exp Parasitol. 1998;89:1–8.
   PubMed Web of Science ®Google Scholar
• Snounou G, Viriyakosol S, Jarra W, et al. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol. 1993;58(2):283–292.
   PubMed Web of Science ®Google Scholar
• Mbacham WF, Evehe MB, Netongo PM, et al. Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy. Malar J. 2010;9:34.
   PubMed Web of Science ®Google Scholar
• Kublin JG, Cortese JF, Njunju EM, et al. Re-emergence of chloroquine-sensitive plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870–1875.
   PubMed Web of Science ®Google Scholar
• Mbaye BAD, Ndiaye YD, et al.selection of n86f184d1246 haplotype of pfmrd1 gene by artemether- lumefantrine drug pressure on plasmodium falciparum populations in Senegal Malar J 151 article no. 433, 2016
   PubMedGoogle Scholar
• Sisowath C, Stromberg J, Mårtensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86 N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191:1014–1017.
   PubMed Web of Science ®Google Scholar
• Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible Pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750–757.
   PubMed Web of Science ®Google Scholar
• Ndam NT, Basco LK, Ngane VF, et al. Re-emergence of chloroquine-sensitive Pfcrt K76 Plasmodium falciparum genotype in South-Eastern Cameroon. Malar J. 2017;16:130.
   PubMedGoogle Scholar
• Fröberg G, Jörnhagen L, Morris U, et al. A. Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar. Malar J. 2012;11:321.
   PubMedGoogle Scholar
• Mbogo GW, Nankoberanyi S, Tukwasibwe S, et al. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg. 2014;91(1):54–61.
   PubMed Web of Science ®Google Scholar
• Bigoga JD, Manga L, Titanji VPK, et al. Malaria vectors and transmission dynamics in coastal South-western Cameroon. Malar J. 2007;6:5.
   PubMed Web of Science ®Google Scholar
• Mason DP, McKenzie FE, Bossert FE. The blood-stage dynamics of mixed Plasmodium malariae-Plasmodium falciparum infection. J Theor Biol. 1999;198:549–566.
   PubMed Web of Science ®Google Scholar
• Eiam-Ong S. Malaria nephropathy. Semin Nephrol. 2003;23(1):21–33.
   PubMedGoogle Scholar
• Fru-Cho JB, Safeukui V, Nkuo-Akenji I, et al. Molecular typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of Cameroon. Malaria Journal. 2014;13(1):170
   Google Scholar
• Moyeh MN, Ali IM, Njimoh DL, et al. Comparison of the accuracy of four malaria diagnostic methods in a high transmission setting in coastal Cameroon. J Parasitol Res. 2019;2019. 10.1155/2019/1417967. Article ID 1417967.
   PubMedGoogle Scholar